Expression of epithelial cell adhesion molecule and molecular subtypes and prognosis of breast cancer / 中南大学学报(医学版)
Zhongnan Daxue xuebao. Yixue ban
; (12): 258-263, 2016.
Article
in Zh
| WPRIM
| ID: wpr-815044
Responsible library:
WPRO
ABSTRACT
OBJECTIVE@#To investigate clinicopathological and prognostic significance of epithelial cell adhesion molecule (EpCAM) expression in breast cancer and its molecular subtypes.
@*METHODS@#The expression of EpCAM in 835 patients with breast invasive ductal carcinoma was detected by immunohistochemical Max VisionTM method, and its correlation with clinical pathological features and prognosis was analyzed.
@*RESULTS@#The positive expression of EpCAM was related to histological grade, lymph node metastasis, tumor size, clinical stage, the expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 (P<0.05). The positive expression rates of EpCAM were 19.2%, 73%, 48.9%, 72.2%, and 62.1%, in Luminal A, Luminal B (HER2-), Luminal B(HER2+), HER2+, and triple-negative subtype, respectively. Log-rank test and univariate COX analysis showed that the EpCAM expression was associated with a poor prognosis in all patients (P<0.001), as well as the triple-negative subtype, luminal B subtype (HER2-), and HER2+ subtype (P<0.05). Multivariate COX analysis showed that EpCAM expression was associated with the survival in patients with the triple-negative or HER2+ subtype (P<0.05).
@*CONCLUSION@#EpCAM may be associated with progress of breast cancer. It is an independent prognostic factor in breast cancer, especially in the triple-negative and HER2+ subtypes.
Full text:
1
Index:
WPRIM
Main subject:
Prognosis
/
Breast Neoplasms
/
Receptors, Progesterone
/
Receptor, ErbB-2
/
Epithelial Cell Adhesion Molecule
/
Lymphatic Metastasis
Type of study:
Prognostic_studies
Limits:
Humans
Language:
Zh
Journal:
Zhongnan Daxue xuebao. Yixue ban
Year:
2016
Type:
Article